Aggressive RAAS Blockade: Should we change our practice?
(
00:00
/34:12)
Outline
1. Aggressive RAAS Blockad
2. Disclosures
3.
4. Objectives
5.
6.
7. Outline-Increasing RAAS
8. Outline-Increasing RAAS
9.
10. ARB and Nephropathy
11. Change in Proteinuria
12. Outline-Increasing RAA
13. Heart Failure
14. Heart Failure-ACEI+ARB
15. Questions
16. Renal Outcomes
17.
18.
19. ACEI+ARB and Nephropat
20. High Dose Candesartan
21. Blocking Aldosterone
22. Aliskiren
23.
24. High Dose Monotherapy
25. High Dose Monotherapy
26. ACEI+ARB:Non-DM
27.
28. Outline-Increasing RAA
29.
30. Clinical Trial Program
31.
32. Vascular Protection: A
33. Questions
34.
35. Questions
36.
37. ONTARGET:Tolerability/
38. ONTARGET:Tolerability/
39.
40. ONTARGET-Combo vs. ram
41.
42.
43. Change in eGFR-ONTARGE
44. Dialysis
45. Dialysis
46. Dialysis
47. Questions
48.
49.
50. ONTARGET-ACR
51.
52.
53. Progression from MA to
54.
55. Normal GFR values
56. Annual hange in GFR
57.
58. Rate of ESRD
59.
60. Is ONTARGET a Renal Ri
61. Overt Nephropathy
62.
63. ONTARGET
64. Change in Proteinuria
65. Conclusion
66.
Thumbnails
1. Aggressive RAAS Blockad
2. Disclosures
3.
4. Objectives
5.
6.
7. Outline-Increasing RAAS
8. Outline-Increasing RAAS
9.
10. ARB and Nephropathy
11. Change in Proteinuria
12. Outline-Increasing RAA
13. Heart Failure
14. Heart Failure-ACEI+ARB
15. Questions
16. Renal Outcomes
17.
18.
19. ACEI+ARB and Nephropat
20. High Dose Candesartan
21. Blocking Aldosterone
22. Aliskiren
23.
24. High Dose Monotherapy
25. High Dose Monotherapy
26. ACEI+ARB:Non-DM
27.
28. Outline-Increasing RAA
29.
30. Clinical Trial Program
31.
32. Vascular Protection: A
33. Questions
34.
35. Questions
36.
37. ONTARGET:Tolerability/
38. ONTARGET:Tolerability/
39.
40. ONTARGET-Combo vs. ram
41.
42.
43. Change in eGFR-ONTARGE
44. Dialysis
45. Dialysis
46. Dialysis
47. Questions
48.
49.
50. ONTARGET-ACR
51.
52.
53. Progression from MA to
54.
55. Normal GFR values
56. Annual hange in GFR
57.
58. Rate of ESRD
59.
60. Is ONTARGET a Renal Ri
61. Overt Nephropathy
62.
63. ONTARGET
64. Change in Proteinuria
65. Conclusion
66.
Notes
MAU: Summary
Time: 01 min 17 sec
Search
Search in
Slide text
Slide notes
Slide titles
References
Slide
01
/66
00:00
/ 34:12
